{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:58:00Z","timestamp":1762642680736,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AIR@InnoHK administered by Innovation and Technology Commission of the Hong Kong SAR Government","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020T130095ZX(MS)"],"award-info":[{"award-number":["2020T130095ZX(MS)"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The ongoing global pandemic of COVID-19 poses unprecedented public health risks for governments and societies around the world, which have been exacerbated by the emergence of SARS-CoV-2 variants. Pharmaceutical interventions with high antiviral efficacy are expected to delay and contain the COVID-19 pandemic. Molnupiravir, as an oral antiviral prodrug, is active against SARS-CoV-2 and is now (23 February 2022) one of the seven widely-used coronavirus treatments. To estimate its antiviral efficacy of Molnupiravir, we built a granular mathematical within-host model. We find that the antiviral efficacy of Molnupiravir to stop the growth of the virus is 0.56 (95% CI: 0.49, 0.64), which could inhibit 56% of the replication of infected cells per day. There has been good progress in developing high-efficacy antiviral drugs that rapidly reduce viral load and may also reduce the infectiousness of treated cases if administered as early as possible.<\/jats:p>","DOI":"10.3390\/v14040763","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T22:23:23Z","timestamp":1649370203000},"page":"763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antiviral Efficacy of Molnupiravir for COVID-19 Treatment"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuan","family":"Bai","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingwang","family":"Shen","sequence":"additional","affiliation":[{"name":"China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi\u2019an Jiaotong University Health Science Center, Xi\u2019an 710061, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi\u2019an Jiaotong University Health Science Center, Xi\u2019an 710061, China"},{"name":"Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC 3004, Australia"},{"name":"Central Clinical School, Faculty of Medicine, Monash University, Melbourne, VIC 3800, Australia"},{"name":"Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"eabc0764","DOI":"10.1126\/sciadv.abc0764","article-title":"Mobile Phone Data for Informing Public Health Actions across the COVID-19 Pandemic Life Cycle","volume":"6","author":"Oliver","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.abc4887","article-title":"A COVID-19 Recovery for Climate","volume":"368","author":"Rosenbloom","year":"2020","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Zimmer, C., Wu, K.J., Corum, J., and Kristoffersen, M. (The New York Times, 2020). Coronavirus Drug and Treatment Tracker, The New York Times."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kozlov, M. (2021). Merck\u2019s COVID Pill Loses Its Lustre: What That Means for the Pandemic. Nature.","DOI":"10.1038\/d41586-021-03667-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"210082","DOI":"10.1098\/rsos.210082","article-title":"Comparing Antiviral Strategies against COVID-19 via Multiscale within-Host Modelling","volume":"8","author":"Fatehi","year":"2021","journal-title":"R. Soc. Open Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/psp4.12543","article-title":"Timing of Antiviral Treatment Initiation Is Critical to Reduce SARS-CoV-2 Viral Load","volume":"9","author":"Bertrand","year":"2020","journal-title":"CPT Pharm. Syst. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hernandez Vargas, E.A., and Velasco-Hernandez, J.X. (2020). In-Host Modelling of COVID-19 Kinetics in Humans. Infect. Dis. (Except HIV\/AIDS).","DOI":"10.1101\/2020.03.26.20044487"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2000062","DOI":"10.2807\/1560-7917.ES.2020.25.5.2000062","article-title":"Incubation Period of 2019 Novel Coronavirus (2019-nCoV) Infections among Travellers from Wuhan, China, 20\u201328 January 2020","volume":"25","author":"Backer","year":"2020","journal-title":"Euro. Surveill."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological Assessment of Hospitalized Patients with COVID-2019","volume":"581","author":"Corman","year":"2020","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/psp4.12500","article-title":"Efficient Pharmacokinetic Modeling Workflow with the MonolixSuite: A Case Study of Remifentanil","volume":"9","author":"Traynard","year":"2020","journal-title":"CPT Pharm. Syst. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e69340","DOI":"10.7554\/eLife.69340","article-title":"Revisiting the Guidelines for Ending Isolation for COVID-19 Patients","volume":"10","author":"Jeong","year":"2021","journal-title":"Elife"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s42979-021-00919-8","article-title":"Within Host Dynamics of SARS-CoV-2 in Humans: Modeling Immune Responses and Antiviral Treatments","volume":"2","author":"Ghosh","year":"2021","journal-title":"SN Comp. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.arcontrol.2020.09.006","article-title":"In-Host Mathematical Modelling of COVID-19 in Humans","volume":"50","year":"2020","journal-title":"Annu. Rev. Control"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jenner, A.L., Aogo, R.A., Alfonso, S., Crowe, V., Deng, X., Smith, A.P., Morel, P.A., Davis, C.L., Smith, A.M., and Craig, M. (2021). COVID-19 Virtual Patient Cohort Suggests Immune Mechanisms Driving Disease Outcomes. PLoS Pathog., 17.","DOI":"10.1101\/2021.01.05.425420"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A Phase 2a Clinical Trial of Molnupiravir in Patients with COVID-19 Shows Accelerated SARS-CoV-2 RNA Clearance and Elimination of Infectious Virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/s41467-020-16585-y","article-title":"Modeling Mitigation of Influenza Epidemics by Baloxavir","volume":"11","author":"Du","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vegvari, C., Hadjichrysanthou, C., Cau\u00ebt, E., Lawrence, E., Cori, A., de Wolf, F., and Anderson, R.M. (2016). How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158237"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110168","DOI":"10.1016\/j.chaos.2020.110168","article-title":"Effect of the Early Use of Antivirals on the COVID-19 Pandemic. A Computational Network Modeling Approach","volume":"140","author":"Benlloch","year":"2020","journal-title":"Chaos Solitons Fractals"},{"key":"ref_20","unstructured":"Office of the Commissioner (2020, July 17). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014Preliminary Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate Use of Remdesivir for Patients with Severe COVID-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2020). Dexamethasone in Hospitalized Patients with COVID-19\u2014Preliminary Report. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:14Z","timestamp":1760136554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/4\/763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["v14040763"],"URL":"https:\/\/doi.org\/10.3390\/v14040763","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}